Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures

Thrombosis and Haemostasis

Volumn 109, Issue 5, 2013, Pages 808-816

  Dahlen, Jeffrey R ^a   Price, Matthew J ^b   Parise, Helen ^c   Gurbel, Paul A ^d  

^a Accumetrics Inc   (United States)

^b SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiplatelet agents; Platelet function testing; Platelet reactivity; Test statistics

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PRASUGREL; PROSTAGLANDIN E1; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; TROPONIN; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DOSE RESPONSE; HUMAN; ISCHEMIA; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PLATELET REACTIVITY; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS;

BLOOD PLATELETS; DRUG RESISTANCE; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84877060794     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-08-0608     Document Type: Article

References (70)

1. Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation 2010; 121: 569-583
2. Helton TJ, Bavry AA, Kumbhani DJ, et al. Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. Am J Cardiovasc Drugs 2007; 7: 289-297
3. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
4. Herman CR, Buth KJ, Kent BA, et al. Clopidogrel increases blood transfusion and hemorrhagic complications in patients undergoing cardiac surgery. Ann Thorac Surg 2010; 89: 397-402
5. Baracchini C, Gruppo M, Mazzalai F, et al. Predictors of neck bleeding after eversion carotid endarterectomy. J Vasc Surg 2011; 54: 699-705
6. Berger JS, Frye CB, Harshaw Q, et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol 2008; 52: 1693-1701
7. Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med 2003; 3: 113-122
8. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996; 76: 939-943
9. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173
10. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-1047
11. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015
12. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057
13. Michelson AD. Methods for the Measurement of Platelet Function. Am J Cardiol 2009; 103 (Suppl): 20A-26A.
14. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
15. O'Brien JR. Platelet aggregation. Part II: some results of a new method. J Clin Pathol 1962; 15: 452-455
16. Steinhubl SR. The VerifyNow system. In: Platelets. 2nd ed. San Diego: Elsevier/ Academic Press, 2007; pp. 509-518
17. Malinin A, Pokov A, Swaim L, et al. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006; 28: 315-322
18. Schwarz UR, Geiger J, Walter U, et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets--definition and detection of ticlopidine/ clopidogrel effects. Thromb Haemost 1999; 82: 1145-1152
19. Tóth O, Calatzis A, Penz S, et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788
20. Liang Y, Johnston M, Hirsh J, et al. Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin. J Thromb Thrombolysis 2012; 34: 429-436
21. Varenhorst C, James S, Erlinge D, et al. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J 2009; 157: 562.e1-9
22. Bouman HJ, Parlak E, van Werkum JW, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010; 8: 482-488
23. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933
24. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913
25. Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392-1396
26. Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85-92
27. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-1826
28. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of postclopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000
29. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a pointof- care assay: a 12-month follow-up. Circulation 2009; 119: 237-242
30. Patti G, Nusca A, Mangiacapra F, et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008; 52: 1128-1133
31. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762
32. Campo G, Fileti L, de Cesare N, et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol 2010; 56: 1447-1455
33. Suh JW, Lee SP, Park KW, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011; 57: 280-289
34. Aradi D, Komócsi A, Vorobcsuk A, et al. Prognostic significance of high onclopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010; 160: 543-551
35. Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58: 1945-1954
36. Ahn SG, Lee SH, Yoon JH, et al. Different Prognostic Significance of High On- Treatment Platelet Reactivity as Assessed by the VerifyNow P2Y12 Assay After Coronary Stenting in Patients With and Without Acute Myocardial Infarction. JACC Cardiovasc Interv 2012; 5: 259-267
37. Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011; 124: 1132-1137
38. Yamaguchi Y, Abe T, Sato Y, et al. Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: A systematic review and meta-analysis. Platelets 2012; epub ahead of print.
39. Effient prescribing information. Available at: http://pi.lilly.com/us/effient.pdf. Accessed August 1, 2012
40. Brilinta prescribing information. Available at: http://www1.astrazeneca-us.com/pi/brilinta.pdf. Accessed August 1, 2012
41. Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57: 2474-2483
42. Department of Vermont Health Access Pharmacy Benefit Management Program DUR Board Meeting Minutes: 02/21/2012. Available at: http://dvha.vermont.gov/advisory-boards/a2-vt-dur-board-minutes-final-022112.pdf. Accessed August 12, 2012
43. The Prescriber e-letter. 2012;5:1-4. Available at: http://www.mass.gov/eohhs/docs/masshealth/pharmacy/precriber-e-letter-feb2012.pdf. Accessed August 12, 2012
44. Plavix prescribing information. Available at: http://products.sanofi.us/PLAVIX/PLAVIX.html. Accessed August 1, 2012
45. Collyer TC, Reynolds HC, Truyens E, et al. Perioperative management of clopidogrel therapy: the effects on in-hospital cardiac morbidity in older patients with hip fractures. Br J Anaesth 2011; 107: 911-915
46. Chassot PG, Marcucci C, Delabays A, et al. Perioperative antiplatelet therapy. Am Fam Physician 2010; 82: 1484-1489
47. Ferraris VA, Brown JR, Despotis GJ, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91: 944-982
48. Brizzio ME, Shaw RE, Bosticco B, et al. Use of an objective tool to assess platelet inhibition prior to off-pump coronary surgery to reduce blood usage. J Invasive Cardiol 2012; 24: 49-52
49. Mahla E, Suarez TA, Bliden KP, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012; 5: 261-269
50. Pletcher MJ, Pignone M. Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact. Circulation 2011; 123: 1116-1124
51. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. J Am Coll Cardiol 2007; 50: 2173-2195
52. Apple FS, Parvin CA, Buechler KF, et al. Validation of the 99th percentile cut-off independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction. Clin Chem 2005; 51: 2198-2200
53. Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyser: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007; 119: 277-284
54. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-577
55. Youden WJ. An index for rating diagnostic tests. Cancer 1950; 3: 32-35
56. Spitalnic S. Test properties 2: likelihood ratios, Bayes' formula, and receiver operating characteristic curves. Hosp Physician 2004; 40: 53-58
57. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172
58. Cook, NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928-935
59. Pencina MJ, D'Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010; 48: 1703-1711
60. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11-21
61. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009; 150: 795-802
62. Wilson JM, Jungner YG. Principles and practice of screening for disease. Geneva, World Health Organisation; 1968
63. Esposito G. Responsiveness to P2Y12 receptor inhibitors. Curr Opin Cardiol 2011; 26 (Suppl 1): S31-37
64. Krishna V, Diamond GA, Kaul S. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven. Circulation 2012; 125: 1288-1303
65. Mathew V, Gersh BJ, Williams BA, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004; 109: 476-480
66. Dahlen JR, Swaim L, Serebruany V. Comparative Effectiveness of the VerifyNow P2Y12 Test and Light Transmittance Aggregometry for Assessing the Antiplatelet Effect of Clopidogrel. Clin Chem 2012; 58 (Suppl): A167-168
67. Wilson PW, Pencina M, Jacques P, et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008; 1: 92-97
68. Polak JF, Pencina MJ, Pencina KM, et al. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 2011; 365: 213-221
69. Erbel R, Möhlenkamp S, Moebus S, et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol 2010; 56: 1397-1406
70. Sivapalaratnam S, Boekholdt SM, Trip MD, et al. Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart 2010; 96: 1985-1989.